Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

6 results about "Lovastatine" patented technology

An analysis method for evaluating the quality of monascus based on HPLC fingerprint and multi-component quantification

PendingCN122259757AComponent separationBiotechnologyHplc fingerprint
This invention proposes an analytical method for evaluating the quality of red yeast rice based on HPLC fingerprinting and multi-component quantitative analysis, belonging to the field of quality control technology for red yeast rice and related products. The method includes: taking a red yeast rice sample, ultrasonically extracting it with 50% methanol, centrifuging, and filtering to prepare a test solution; performing detection using high-performance liquid chromatography; constructing a red yeast rice fingerprint chromatogram based on the detection results, and simultaneously determining the content of six active ingredients: ankaflavin, citrinin, lactone-type mevastatin, lactone-type lovastatin, acid mevastatin, and acid lovastatin; and combining chemical pattern recognition methods to perform discriminant analysis on red yeast rice samples from different sources to evaluate the quality of the red yeast rice. This invention achieves an organic combination of simultaneous quantitative analysis of multiple components in red yeast rice and overall quality evaluation based on fingerprint chromatograms. Methodological validation shows that this method has good precision, repeatability, and stability, and is accurate and reliable, suitable for the quality control of red yeast rice raw materials and health foods and pharmaceuticals containing red yeast rice.
Owner:HUNAN UNIV OF CHINESE MEDICINE

A medicament for inhibiting formation of zanthoxylum bungeanum maxim thorns and a preparation method thereof

PendingCN122350094AGlycineSucrose
This invention discloses a medicament for inhibiting the formation of thorns in Sichuan pepper, relating to the field of Sichuan pepper cultivation technology. The medicament comprises the following components at final concentrations: lovastatin 5-20 mg / L, 6-mercaptopurine 5-10 mg / L, pyrimidinol 10-30 mg / L, proline 20-100 mg / L, glycine 20-100 mg / L, glutamic acid 20-100 mg / L, potassium dihydrogen phosphate 5-7 mg / L, sucrose 5-7 mg / L, and Tween-80 1-2 mg / L. This invention also provides a method for preparing the medicament for inhibiting the formation of thorns in Sichuan pepper. This invention reduces the incidence of thorns in Sichuan pepper, with a significant thorn-inhibiting effect. While inhibiting thorn formation, it also increases the growth of new shoots in Sichuan pepper, effectively solving the problem that single-hormone inhibitors easily lead to excessive shoot growth, decreased flower bud differentiation rate, or reduced fruit weight.
Owner:CHONGQING UNIV OF ARTS & SCI

Rosuvastatin spherical crystal, its preparation method and application

PendingCN122444679APhysical chemistryCrystal habit
The application relates to a lovastatin spherical crystal and a preparation method and application thereof, which comprises the following steps: under the condition that the stirring speed is 150-500 r / min, the volume ratio of a lovastatin saturated solution with a temperature of 40-75 DEG C to water is 1:2-1:100, the lovastatin saturated solution is added into water with a constant temperature of 5-35 DEG C, and then lovastatin spherical crystals are obtained. The lovastatin spherical crystal has a particle size range of 0.1-5.0 mm, a Hausner ratio of 1.08-1.15, a bulk density of 0.20-0.40 g / mL, and a compacted density of 0.20-0.45 g / mL. The anti-blocking ability of the prepared lovastatin spherical crystal is strong, the problems of filtration difficulty, poor flowability and production, storage, preparation and the like caused by the needle-like crystal habit of lovastatin are solved, the operation is simple and efficient, and the industrialized scale implementation is easy.
Owner:JIANGXI NORMAL UNIV

Compound fat-reducing functional tablet candy of coix seed and red yeast rice and preparation method and application thereof

PendingCN122320112ABiotechnologyRed yeast rice
The present application relates to the technical field of functional food preparation and development of resources of medicinal and edible origin, and specifically relates to a compound lipid-lowering functional tablet candy of coix seed and red koji and a preparation method thereof. The present application realizes the synergistic promotion of active ingredient enrichment, stable processing characteristics and efficient lipid-lowering effect through precise control of the solid-state fermentation process of coix seed by Monascus purpureus and formula optimization based on the AHP-CRITIC mixed weighting method. The content of lovastatin in the tablet candy of the present application is 1.35 times that of the same type of commercially available red koji product, the content of phytosterols (especially ergosterol) is more than 4 times that of commercially available products, and the product retains the coixol component that is not detected in commercially available products. The raw materials of the present application are all resources of medicinal and edible origin or food-grade auxiliary materials, and have high long-term safety. The tablet candy has high standardization, is easy to take and store stably, and meets the convenience needs of consumers for daily health management.
Owner:TONGJITANG CHINESE MEDICINES CO +1

Wound treatments and compositions

A method of treating a wound may include topically administering a statin composition including a statin selected from atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, or combination thereof. The statin composition may be administered in an ointment, powder, or liquid format. The method may also include topically administering one or more antimicrobial drugs and / or naltrexone.
Owner:CMPD LICENSING LLC

Monascus strain capable of producing monascin and / or ankaflavin with high yield and use thereof

PCT designated stageWO2026145497A1BiotechnologyLiver and kidney
Provided are a monascus strain capable of producing monascin and / or ankaflavin and the use thereof. Particularly, provided are a new monascus strain assigned with the accession number CGMCC NO. 41335 and the use thereof in the production of high-content monascin and / or ankaflavin and related products thereof. The strain is Monascus purpureus ZYXQ-2206, can produce potent and non-toxic lipid-lowering ingredients monascin and / or ankaflavin with a high yield, and does not produce harmful and toxic ingredients lovastatin (LOV) and citrinin (CIT). Since excessive intake of LOV can cause serious side effects such as liver and kidney injury and rhabdomyolysis, and excessive intake of CIT can cause toxic responses such as renal tubular dilation and degeneration and necrosis of epithelial cells, the monascus products produced by using the strain can effectively avoid these safety risks, and have extremely high application prospects and market potentials. By screening and optimizing a fermentation process, the monascus strain having high productivity, no toxicity and high functionality is provided, which has significant application value in the fields of development of lipid-lowering functional foods and dietary supplements.
Owner:BEIJING SCICURECANCER TECH CO LTD